Contrasting CardioGenics (OTCMKTS:CGNH) and Beta Bionics (NASDAQ:BBNX)

CardioGenics (OTCMKTS:CGNH) and Beta Bionics (NASDAQ:BBNX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for CardioGenics and Beta Bionics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Beta Bionics	1	3	6	1	2.64

Beta Bionics has a consensus target price of $19.70, indicating a potential upside of 41.83%. Given Beta Bionics’ stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than CardioGenics.

Profitability

This table compares CardioGenics and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Beta Bionics	-60.27%	-23.00%	-20.55%

Earnings & Valuation

This table compares CardioGenics and Beta Bionics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Beta Bionics	$100.25 million	6.17	-$73.20 million	($1.51)	-9.20

CardioGenics has higher earnings, but lower revenue than Beta Bionics.

Summary

Beta Bionics beats CardioGenics on 5 of the 8 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.